RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
The purpose of this study is to compare the effects, good and/or bad, of radiation therapy and cisplatin versus radiation therapy with cetuximab.
1. Proven diagnosis of squamous cell carcinoma of the oropharynx
2. General history and physical examination by a radiation oncologist and medical oncologist within 8 weeks prior to registration
3. Examination by an ENT or head and neck surgeon, including laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 8 weeks prior to registration
4. Age ≥ 18
5. Other eligibility criteria also apply
18 - 99
Healthy Volunteers Needed
Duration of Participation
The treatment phase of the study will last for up to 8 weeks. After that you will be asked to visit the office for follow up at 1 and 3 months from the end of treatment, then every 3 months through year 2, every 6 months for 3 years, then once a year for your lifetime.
Knight Clinical Trials Information Line